Oncolytics Biotech (TSE:ONC) Shares Down 1.6% – What’s Next?

Shares of Oncolytics Biotech Inc. (TSE:ONC) dropped 1.6% during trading on Thursday . The stock traded as low as C$1.18 and last traded at C$1.20. Approximately 123,141 shares were traded during mid-day trading, an increase of 72% from the average daily volume of 71,561 shares. The stock had previously closed at C$1.22.

Wall Street Analyst Weigh In

Separately, Raymond James upgraded shares of Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th.

Oncolytics Biotech Stock Down 1.6 %

The stock’s fifty day moving average price is C$1.52 and its 200 day moving average price is C$1.42. The company has a current ratio of 4.99, a quick ratio of 8.86 and a debt-to-equity ratio of 6.09. The stock has a market cap of C$92.23 million, a P/E ratio of -3.16 and a beta of 1.35.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.